Efficacy of living liver transplantation in the treatment of pediatric acute liver failure and chronic end-stage liver disease
裴家好,沈丛欢,李瑞东,陶一峰,谢新宝,陈伟明,王正昕
DOI: https://doi.org/10.3877/cma.j.issn.1674-3903.2021.06.002
2021-01-01
Abstract:Objective:To explore the effect of living liver transplantation in the treatment of pediatric acute liver failure (ALF), and to compare with the effect of children with chronic end-stage liver disease also treated with living liver transplantation.Methods:The clinical data of 100 pediatric liver transplantation recipients in Huashan Hospital of Fudan University from October 2016 to June 2020 were retrospectively analyzed, and the recipients were divided into ALF group (n=17) and chronic end-stage liver disease group (n=83) according to the primary disease. General data were collected, including sex, age, body mass index, pediatric end-stage liver disease model (PELD) score, graft and recipient weight ratio and blood type matching. The incidence of perioperative complications, postoperative long-term complications, and the survival of the recipients and grafts at 1 and 3 years after transplantation were observed in the two groups. The measurement data conforming to normal distribution were compared by group t test. Non-normal distribution measurement data were compared by Mann-Whitney U test. The counting data were compared with Chi-square test. Kaplan-Meier method was used to draw the survival curve of the two groups, and log-rank test was used to compare the survival rate. A P<0.05 was considered statistically significant.Results:PELD scores of ALF group and chornic end-stage liver disease group were (33±10) and (17±12), respectively, and the difference was statistically significant (t=5.138, P<0.05). There were 10 recipients (11 cases) with perioperative complications in ALF group, including 5 cases of surgery-related surgical complications, 4 cases of infection, 1 case of acute rejection, and 1 case of biliary tract complication. Long-term complications were reported in 2 recipients. There were 41 recipients (41 cases) with perioperative complications in chronic end-stage liver disease group, including 10 cases of surgery-related surgical complications, 10 cases of infection, 10 cases of acute rejection, 6 cases of biliary tract complications, and 5 cases of vascular complications. There were 7 recipients with postoperative long-term complications, including anastomotic stenosis of vena cava in 2 recipients, portal vein stenosis in 2 recipients, intestinal obstruction in 1 recipient, biliary tract stenosis in 1 recipient, and epstein-barr virus infection secondary post transplant lymphoproliferative disorder after transplantation in 1 recipient. During the follow-up, 3 recipients in the ALF group and 5 recipients in the chronic end-stage liver disease group died. In the ALF group, the 1-year and 3-year cumulative survival rates of recipients were 82.4% and 82.4%, respectively, and the grafts survival rates were 82.4% and 82.4%, respectively. The 1-year and 3-year cumulative survival rates of recipients in the chronic end-stage liver disease group were 94.0% and 94.0%, respectively, and the grafts survival rates were 94.0% and 94.0%, respectively. There was no significant difference in the 3-year cumulative survival rates of recipients and grafts between the two groups (χ2=1.251 and 1.251, all P>0.05).Conclusion:Living liver transplantation is effective in the treatment of ALF in children and can achieve the same prognosis as chronic end-stage liver disease in children.